Carregant...
Diminished sensitivity of Chronic Lymphocytic Leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood
PURPOSE: Inhibition of the anti-apoptotic BCL2 family is one of the most promising areas of anti-cancer drug development. However, ABT-737, a specific BCL2 inhibitor, is neither orally bioavailable nor metabolically stable. To overcome these problems, the structurally related molecule, ABT-263, was...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2921948/ https://ncbi.nlm.nih.gov/pubmed/20601444 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0777 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|